p.111 抽出テキスト

brain natriuretic peptide (N-BNP) concentrations. Lancet 2000;355: 1126–30. https://doi.org/10.1016/s0140-6736(00)02060-2 1059. Troughton R, Michael Felker G, Januzzi JL Jr. Natriuretic peptide-guided heart failure management. Eur Heart J 2014;35:16–24. https://doi.org/10. 1093/eurheartj/eht463 1060. McLellan J, Heneghan CJ, Perera R, Clements AM, Glasziou PP, Kearley KE, et al. B-type natriuretic peptide-guided treatment for heart failure. Cochrane Database Syst Rev 2016;12:CD008966. https://doi.org/10. 1002/14651858.CD008966.pub2 1061. Goldstein NE, Mather H, McKendrick K, Gelfman LP, Hutchinson MD, Lampert R, et al. Improving communication in heart failure patient care. J Am Coll Cardiol 2019;74:1682–92. https://doi.org/10.1016/j.jacc.2019. 07.058 1062. O’Donnell AE, Schaefer KG, Stevenson LW, DeVoe K, Walsh K, Mehra MR, et al. Social worker-aided palliative care intervention in high-risk patients with heart failure (SWAP-HF): a pilot randomized clinical trial. JAMA Cardiol 2018;3:516–9. https://doi.org/10.1001/jamacardio.2018.0589 1063. Rogers JG, Patel CB, Mentz RJ, Granger BB, Steinhauser KE, Fiuzat M, et al. Palliative care in heart failure: the PAL-HF randomized, controlled clinical trial. J Am Coll Cardiol 2017;70:331–41. https://doi.org/10.1016/j.jacc. 2017.05.030 1064. Datla S, Verberkt CA, Hoye A, Janssen DJA, Johnson MJ. Multi-disciplinary palliative care is effective in people with symptomatic heart failure: a systematic review and narrative synthesis. Palliat Med 2019;33:1003–16. https://doi.org/10.1177/0269216319859148 1065. Fendler TJ, Swetz KM, Allen LA. Team-based palliative and end-of-life care for heart failure. Heart Fail Clin 2015;11:479–98. https://doi.org/10.1016/j. hfc.2015.03.010 1066. Sahlollbey N, Lee CKS, Shirin A, Joseph P. The impact of palliative care on clinical and patient-centred outcomes in patients with advanced heart failure: a systematic review of randomized controlled trials. Eur J Heart Fail 2020;22:2340–6. https://doi.org/10.1002/ejhf.1783 1067. Diop MS, Rudolph JL, Zimmerman KM, Richter MA, Skarf LM. Palliative care interventions for patients with heart failure: a systematic review and meta-analysis. J Palliat Med 2017;20:84–92. https://doi.org/10.1089/jpm. 2016.0330 1068. Zhou K, Mao Y. Palliative care in heart failure: a meta-analysis of randomized controlled trials. Herz 2019;44:440–4. https://doi.org/10.1007/ s00059-017-4677-8 1069. Eggleton EJ, McMurrugh KJ, Aiken CE. Maternal pregnancy outcomes in women with cardiomyopathy: a systematic review and meta-analysis. Am J Obstet Gynecol 2022;227:582–92. https://doi.org/10.1016/j.ajog.2022. 05.039 1070. Mehta LS, Sharma G, Creanga AA, Hameed AB, Hollier LM, Johnson JC, et al. Call to action: maternal health and saving mothers: a policy statement from the American Heart Association. Circulation 2021;144:e251–69. https://doi.org/10.1161/CIR.0000000000001000 1071. Ruys TP, Roos-Hesselink JW, Hall R, Subirana-Domenech MT, Grando-Ting J, Estensen M, et al. Heart failure in pregnant women with cardiac disease: data from the ROPAC. Heart 2014;100:231–8. https://doi.org/10.1136/ heartjnl-2013-304888 1072. Tanaka K, Tanaka H, Kamiya C, Katsuragi S, Sawada M, Tsuritani M, et al. Beta-blockers and fetal growth restriction in pregnant women with cardiovascular disease. Circ J 2016;80:2221–6. https://doi.org/10.1253/circj.CJ- 15-0617 1073. Ramlakhan KP, Roos-Hesselink JW, Basso T, Greenslade J, Flint RB, Krieger EV, et al. Perinatal outcomes after in-utero exposure to beta-blockers in women with heart disease: data from the ESC EORP registry of pregnancy and cardiac disease (ROPAC). Int J Cardiol 2024;410:132234. https://doi.org/ 10.1016/j.ijcard.2024.132234 1074. van der Zande JA, Ramlakhan KP, Prokselj K, Munoz-Ortiz E, Baroutidou A, Lipczynska M, et al. ACE inhibitor and angiotensin receptor blocker use during pregnancy: data from the ESC Registry of Pregnancy and Cardiac Disease (ROPAC). Am J Cardiol 2024;230:27–36. https://doi.org/10. 1016/j.amjcard.2024.08.004 1075. Bullo M, Tschumi S, Bucher BS, Bianchetti MG, Simonetti GD. Pregnancy outcome following exposure to angiotensin-converting enzyme inhibitors or angiotensin receptor antagonists: a systematic review. Hypertension 2012;60:444–50. https://doi.org/10.1161/HYPERTENSIONAHA.112. 196352 1076. Muller DRP, Stenvers DJ, Malekzadeh A, Holleman F, Painter RC, Siegelaar SE. Effects of GLP-1 agonists and SGLT2 inhibitors during pregnancy and lactation on offspring outcomes: a systematic review of the evidence. Front Endocrinol (Lausanne) 2023;14:1215356. https://doi.org/10.3389/ fendo.2023.1215356 1077. Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A, et al. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2021;42:1554–68. https://doi.org/10.1093/eurheartj/ehab072 1078. Lane T, Fontana M, Martinez-Naharro A, Quarta CC, Whelan CJ, Petrie A, et al. Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis. Circulation 2019;140:16–26. https://doi.org/10.1161/ CIRCULATIONAHA.118.038169 1079. Ney S, Ihle P, Ruhnke T, Gunster C, Michels G, Seuthe K, et al. Epidemiology of cardiac amyloidosis in Germany: a retrospective analysis from 2009 to 2018. Clin Res Cardiol 2023;112:401–8. https://doi.org/10.1007/s00392- 022-02114-y 1080. Porcari A, Fontana M, Gillmore JD. Transthyretin cardiac amyloidosis. Cardiovasc Res 2023;118:3517–35. https://doi.org/10.1093/cvr/cvac119 1081. Wechalekar AD, Fontana M, Quarta CC, Liedtke M. AL amyloidosis for cardiologists: awareness, diagnosis, and future prospects: JACC: CardioOncology state-of-the-art review. JACC CardioOncol 2022;4: 427–41. https://doi.org/10.1016/j.jaccao.2022.08.009 1082. Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med 2018;379:1007–16. https://doi. org/10.1056/NEJMoa1805689 1083. Gillmore JD, Judge DP, Cappelli F, Fontana M, Garcia-Pavia P, Gibbs S, et al. Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy. N Engl J Med 2024;390:132–42. https://doi.org/10.1056/ NEJMoa2305434 1084. Fontana M, Berk JL, Gillmore JD, Witteles RM, Grogan M, Drachman B, et al. Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy. N Engl J Med 2025;392:33–44. https://doi.org/10.1056/NEJMoa2409134 1085. Judge DP, Gillmore JD, Alexander KM, Ambardekar AV, Cappelli F, Fontana M, et al. Long-term efficacy and safety of acoramidis in ATTR-CM: initial report from the open-label extension of the ATTRibute-CM trial. Circulation 2024;151:601–11. https://doi.org/10.1161/CIRCULATIONAHA.124. 072771 1086. Maurer MS, Kale P, Fontana M, Berk JL, Grogan M, Gustafsson F, et al. Patisiran treatment in patients with transthyretin cardiac amyloidosis. N Engl J Med 2023;389:1553–65. https://doi.org/10.1056/NEJMoa2300757 1087. Ioannou A, Massa P, Patel RK, Razvi Y, Porcari A, Rauf MU, et al. Conventional heart failure therapy in cardiac ATTR amyloidosis. Eur Heart J 2023;44:2893–907. https://doi.org/10.1093/eurheartj/ehad347 1088. Sperry BW, Hanna M, Shah SJ, Jaber WA, Spertus JA. Spironolactone in patients with an echocardiographic HFpEF phenotype suggestive of cardiac amyloidosis: results from TOPCAT. JACC Heart Fail 2021;9:795–802. https://doi.org/10.1016/j.jchf.2021.06.007 1089. Lang FM, Teruya S, Weinsaft A, Cuomo M, Santos AM, Nalbandian A, et al. Sodium–glucose cotransporter 2 inhibitors for transthyretin amyloid cardiomyopathy: analyses of short-term efficacy and safety. Eur J Heart Fail 2024;26:938–47. https://doi.org/10.1002/ejhf.3198 1090. Porcari A, Cappelli F, Nitsche C, Tomasoni D, Sinigiani G, Longhi S, et al. SGLT2 inhibitor therapy in patients with transthyretin amyloid cardiomyopathy. J Am Coll Cardiol 2024;83:2411–22. https://doi.org/10.1016/j.jacc. 2024.03.429 1091. Byer SH, Sivamurugan A, Grewal US, Fradley MG, Dominic P. Impact of sodium–glucose cotransporter-2 inhibitors on cardiovascular outcomes in transthyretin amyloid cardiomyopathy. Am J Cardiol 2025;243:15–18. https://doi.org/10.1016/j.amjcard.2025.01.012 1092. Garcia-Pavia P, Gonzalez-Lopez E, Anderson LJ, Cappelli F, Damy T, Fontana M, et al. Non-amyloid specific treatment for transthyretin cardiac amyloidosis: a clinical consensus statement of the ESC Heart Failure Association. Eur Heart J 2026;47:22–36. https://doi.org/10.1093/ eurheartj/ehaf710 1093. Ioannou A, Cappelli F, Emdin M, Nitsche C, Longhi S, Masri A, et al. Stratifying disease progression in patients with cardiac ATTR amyloidosis. J Am Coll Cardiol 2024;83:1276–91. https://doi.org/10.1016/j.jacc.2023. 12.036 1094. Sinigiani G, Sanna GD, Aimo A, Porcari A, Bonacchi G, De Michieli L, et al. Outcome and disease progression in NYHA functional class I and II patients with wild-type transthyretin cardiomyopathy treated with tafamidis. JACC Heart Fail 2025;13:102549. https://doi.org/10.1016/j.jchf.2025.102549 1095. Writing C, Kittleson MM, Ruberg FL, Ambardekar AV, Brannagan TH, Cheng RK, et al. 2023 ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol 2023;81:1076–126. https://doi.org/10.1016/j.jacc.2022. 11.022 Downloaded from academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehag100/8766302 by guest on 31 August 2026